Your SlideShare is downloading. ×
Hidrasec Bongs Lecture
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Hidrasec Bongs Lecture

7,146

Published on

10th Post Graduate Course PAFP Pangasinan Chapter

10th Post Graduate Course PAFP Pangasinan Chapter

Published in: Health & Medicine, Business
1 Comment
5 Likes
Statistics
Notes
  • good krub
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total Views
7,146
On Slideshare
0
From Embeds
0
Number of Embeds
3
Actions
Shares
0
Downloads
0
Comments
1
Likes
5
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • This slide set is prepared for the Scientific and Interactive Meetings (SIM) to be conducted for Racecadotril (Hidrasec). The title of this module is “A Novel Approach in the Treatment of Acute Diarrhea”.
  • Transcript

    • 1. A Novel Approach in the Treatment of Acute Diarrhea ARBEL MONDONEDO,MD,FPCP, FPSG,FPSDE
    • 2.
      • Fluid and electrolyte balance and diarrhea
      • Burden of diarrhea and its management
      • Racecadotril – an intestinal antisecretory agent
      • Clinical trials
      • Safety and tolerability profile
      • Conclusions
      PRESENTATION OUTLINE INTRODUCTION
    • 3. FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    • 4. DAILY WATER EXCHANGES Sellin JH. Intestinal electrolyte absorption and secretion. In: Feldman M, et al, eds. Sleisenger & Fordtrans Gastrointestinal and Liver Disease . 6 th ed. 1998: 1451-1471 FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES Food Fluid intake Water absorption Water secretion (<5ml/kg – children) (< 200 ml – adults) Exogenous sources: (2 liters) Endogenous sources: (7 liters) Saliva Gastric juices Intestinal secretions Pancreatic juices Biliary secretions
    • 5. Duodenum / Jejunum 5.5 liters Endogenous secretions: intestinal, pancreatic, salivary, biliary and gastric juices 7 liters Sellin JH. Intestinal electrolyte absorption and secretion. In: Feldman M, et al, eds. Sleisenger & Fordtrans. Gastrointestinal and Liver Disease . 6 th ed. 1998: 1451-1471 Ileum 2 liters Colon/ Rectum 1.3 liters Stool (<5ml/kg – children) (< 200 ml – adults) Food and fluid intake (drinks, meals…) 2 liters FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES DAILY WATER EXCHANGES
    • 6. Glucose, Na + , K + , Cl - , Water WATER FOLLOWS THE MOVEMENT OF ELECTROLYTES AND GLUCOSE Gut lumen Enterocyte FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    • 7. Crypt: Secretion Villus Tip: Absorption Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 NORMAL STATE FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    • 8. REGULATION OF INTESTINAL SECRETION Enkephalin - opioid neurotransmitter that binds to delta receptors to reduce the levels of cAMP Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 VIP (Vasoactive Intestinal Peptide) Prostaglandin E 2 - increase cAMP levels Cyclic AMP - induces secretion of water and electrolytes Enkephalinase - enzyme that degrades enkephalins FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    • 9. OPIOIDS AND THEIR RECEPTORS Exogenous - Morphine - Loperamide µ (mu) has inhibitory effects on intestinal smooth muscles  (delta) decreases cAMP formation +++ +++ + + Endogenous - Enkephalins + +++ Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 Opioids Opioid receptors FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    • 10. c-AMP ATP VIP Prostaglandins Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 Enkephalins REGULATION OF WATER AND ELECTROLTYE SECRETION – NORMAL STATE Enkephalinase Delta receptor FLUID AND ELECTROLYTE BALANCE IN THE INTESTINES
    • 11. DIARRHEA
    • 12.
      • Passage of abnormally liquid or unformed stools at an increased frequency
      • Stool weight > 200 grams / day
      DIARRHEA 1,2 1. Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1 2. The Treatment of Diarrhea: A manual for physicians and other senior health workers, Department of Child and Adolescent Health and Development, World Health Organization 2005 Consistency of the stools is more important than the number of stools. Frequent passing of formed stools is NOT diarrhea. DIARRHEA
    • 13. Over-secretion of water leads to diarrhea. Hypersecretion DIARRHEA (> 200 grams /day) Secretion Absorption Absorption Normal State DIARRHEA DIARRHEA
    • 14.
      • Acute diarrhea
      • - < 2 weeks duration
      • - more than 90% are caused by infectious agents
      • - often accompanied by vomiting, fever, and abdominal pain
      • Persistent diarrhea
      • 2 to 4 weeks duration
      • Chronic diarrhea
      • > 4 weeks duration
      • needs further evaluation to exclude serious underlying pathology
      • usually non-infectious in origin
      ACUTE, PERSISTENT, AND CHRONIC DIARRHEA DIARRHEA Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1
    • 15.
      • Bacteria: - ETEC - V. cholerae, V. parahaemolyticus - Aeromonas, Plesiomonas, Shigella, Salmonella , EHEC
      • Viruses: - Rotavirus - Enteric adenovirus (types 40 & 41) - SRSVs
      • Protozoa: - C. parvum, G. intestinalis
      • Duration: < 14 days; lasts several hours or days
      ACUTE WATERY DIARRHEA (Infectious) 1,2 1. Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 2. The Treatment of Diarrhea: A manual for physicians and other senior health workers, Department of Child and Adolescent Health and Development, World Health Organization 2005 DIARRHEA
    • 16. NORMAL VILLI BLUNTED VILLI ACUTE WATERY DIARRHEA (Infectious) DIARRHEA
    • 17. Destruction of enterocytes: EIEC, rotavirus, shigella Defective absorption Hypersecretion: Vibrio cholerae , rotavirus, ETEC, shigella IMBALANCE BETWEEN ABSORPTION AND SECRETION The Treatment of Diarrhea: A manual for physicians and other senior health workers, Department of Child and Adolescent Health and Development, World Health Organization 2005 ACUTE WATERY DIARRHEA (Infectious) DIARRHEA
    • 18. BURDEN OF DIARRHEA
    • 19. More than 1 billion people suffer one or more episodes of acute diarrhea each year. Because of poor sanitation and more limited access to health care, acute infectious diarrhea remains one of the most common causes of mortality in developing countries, particularly among children. BURDEN OF DIARRHEA DIARRHEA IN DEVELOPING COUNTRIES Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1
    • 20. DIARRHEA IN THE PHILIPPINES *rate/100,000 of sex-specific population 2003 Annual Report Field Health Service Information System, 2000 Philippine Health Statistics, Department of Health, Philippines 2nd leading cause of morbidity (general population) BURDEN OF DIARRHEA
    • 21. MANAGEMENT OF DIARRHEA
    • 22.
      • The decision to evaluate acute diarrhea depends on its severity and duration, and on various host factors.
      APPROACH TO THE PATIENT WITH ACUTE DIARRHEA Indications for evaluation: profuse diarrhea with dehydration grossly bloody stools fever ≥ 38.5 o C duration > 48 hours without improvement new community outbreaks severe abdominal pain in patients > 50 years, and elderly or immunocompromised patients MANAGEMENT OF DIARRHEA Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1
    • 23. Fluid and electrolyte replacement are of central importance to all forms of acute diarrhea. MANAGEMENT OF DIARRHEA THE TREATMENT OF ACUTE DIARRHEA In moderately severe, non-febrile and non-bloody diarrhea, antimotility antisecretory agents can be useful adjuncts to control symptoms. Judicious use of antibiotics is appropriate in selected instances of acute diarrhea. Harrison’s Principles of Internal Medicine 17 th Edition. Volume 1
    • 24. UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA
    • 25. LIMITATIONS OF CURRENT THERAPY Fluid replacement - No significant reduction of diarrhea - Diarrhea may continue “ Antidiarrheals” - Limited efficacy - CNS effects - Bloating - Rebound constipation Antibiotics - Resistance - Unwanted adverse effects Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA
    • 26. inhibits fluid secretion by intestinal mucosa has a rapid onset of action has limited constipating effects has a high therapeutic index has minimal central nervous system effects has low abuse potential Edelman R. Prevention and treatment of infectious diarrhea. Speculations on the next 10 years. Am J Med 1985;78:99-106. UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA THE IDEAL TREATMENT FOR ACUTE DIARRHEA
    • 27. Prevention of Dehydration and Control of Diarrhea Fluid replacement alone Fluid replacement with anti-secretory agent UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA THE IDEAL TREATMENT FOR ACUTE DIARRHEA
    • 28. inhibits fluid secretion by intestinal mucosa has a rapid onset of action has limited constipating effects has a high therapeutic index has minimal central nervous system effects has low abuse potential Racecadotril was developed specifically with these characteristics in mind. 2 1. Edelman R. Prevention and treatment of infectious diarrhea. Speculations on the next 10 years. Am J Med 1985;78:99-106. 2. Lecomte JM. International Journal of Antimicrobial Agents 14 (2000) 81-87 THE IDEAL TREATMENT FOR ACUTE DIARRHEA 1 UNMET MEDICAL NEEDS IN THE TREATMENT OF ACUTE DIARRHEA
    • 29. RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    • 30. REGULATION OF INTESTINAL SECRETION Enkephalin - opioid neurotransmitter that binds to delta receptors to reduce the levels of cAMP Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 VIP (Vasoactive Intestinal Peptide) Prostaglandin E 2 - increase cAMP levels Cyclic AMP - induces secretion of water and electrolytes Enkephalinase - enzyme that degrades enkephalins RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    • 31. OPIOIDS AND THEIR RECEPTORS Exogenous - Morphine - Loperamide µ (mu) has inhibitory effects on intestinal smooth muscles  (delta) decreases cAMP formation +++ +++ + + Endogenous - Enkephalins + +++ Farthing M. Digestive Diseases (Review Article) 2006;24:47-58 Opioids Opioid receptors RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    • 32. c-AMP ATP VIP Prostaglandins Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 Enkephalins REGULATION OF WATER AND ELECTROLTYE SECRETION – NORMAL STATE Enkephalinase Delta receptor RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    • 33. c-AMP ATP Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 Enkephalins Enkephalinase Delta receptor Toxic peptides from viruses / bacteria REGULATION OF INTESTINAL SECRETION - HYPERSECRETORY STATE RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    • 34. c-AMP ATP Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 Enkephalins Enkephalinase Delta receptor Toxic peptides from viruses / bacteria Racecadotril MODE OF ACTION OF RACECADOTRIL - NORMALIZATION OF SECRETION RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    • 35. RACECADOTRIL, a prodrug of THIORPHAN, a potent enkephalinase inhibitor Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT RACECADOTRIL THIORPHAN (potent-enkephalinase inhibitor) (Non-specific esterase) Hydrolysis
    • 36. RACECADOTRIL (pro-drug) THIORPHAN (active metabolite) Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT RACECADOTRIL, a prodrug of THIORPHAN, a potent enkephalinase inhibitor
    • 37. As the concentration of thiorphan increases, enkephalin levels also increase. Inactivation of endogenous enkephalins by enkephalinase Schwartz. International Journal of Antimicrobial Agents 14(2000) 75-79 RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT RACECADOTRIL, a prodrug of THIORPHAN, a potent enkephalinase inhibitor
    • 38. Enkephalinase inhibition kinetics in healthy volunteers after a single oral dose (100 mg) Lecomte JM. International Journal of Antimicrobial Agents 14 (2000) 81-87 ONSET OF ACTION OF RACECADOTRIL RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    • 39. ANTI-SECRETORY ACTIVITY OF RACECADOTRIL Primi et al, Alimentary Pharmacology and Therapeutics 1999; 13(Suppl.6): 3-7. RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT Effect of Racecadotril on cholera toxin-induced hypersecretion in dogs
    • 40. Hinterleitner TA et al. Eur J Gastroenterol Hepatol 1997;9:887-91. Effect of Racecadotril (a single oral dose of 300 mg) on cholera toxin-induced water secretion in healthy adult subjects ANTI-SECRETORY ACTIVITY OF RACECADOTRIL RACECADOTRIL: AN INTESTINAL ANTISECRETORY AGENT
    • 41. CLINICAL TRIALS
    • 42. INFANTS AND CHILDREN Eduardo Salazar-Lindo, M.D. et al. The New England Journal of Medicine 2000; 343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN
    • 43.
      • STUDY DESIGN
        • – Randomized, double-blind, placebo-controlled study with 2 parallel groups
      • OBJECTIVE
        • – To assess the efficacy and safety of racecadotril as an adjunct to oral rehydration therapy for children with acute watery diarrhea
      RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.)
      • TREATMENT
        • – Oral rehydration + racecadotril 1.5 mg/kg t.i.d.
        • – Oral rehydration + placebo t.i.d.
      Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 INFANTS AND CHILDREN
    • 44.
      • POPULATION
        • – Racecadotril + ORS: 68 patients
        • – Placebo + ORS: 67 patients
      • EXCLUSION CRITERIA
        • – Patients with diarrhea lasting for more than 5 days, blood in stools, severe dehydration (requiring IV therapy) and other illness
      • INCLUSION CRITERIA
        • – Boys 3 to 35 months of age
        • – Hospitalized because of dehydration
        • – With watery diarrhea for 5 days or less
      Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    • 45.
      • EVALUATION CRITERIA
        • Primary end point : 48-hour stool output (measured in grams)
        • Other end points :
        • – Total stool output
        • – Duration of diarrhea
        • – Total ORS intake
        • Number of adverse events
      Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    • 46.
      • Characteristics of population at inclusion
      Age [months] 13 12 Weight [kg] 9.0 8.7 Duration of diarrhea before inclusion [hrs] 47.4 51.5 Stool number in the last 24 hours 8.6 9.7 Stool consistency [no. of boys] Loose 16 14 Watery 52 53 Characteristic Racecadotril + ORS Placebo + ORS [ n = 68] [n = 67] Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    • 47.
      • 48-hour stool output / body weight (g/kg)
      Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    • 48.
      • Total stool output / body weight (g/kg)
      Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    • 49.
      • Time to recovery
      Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    • 50.
      • Total intake of oral rehydration solution
      Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    • 51.
      • TOLERABILITY
      Adverse Events (%) Racecadotril + ORS 10 Placebo + ORS 7 The incidence of vomiting did not differ between the racecadotril and placebo groups. Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    • 52. Salazar-Lindo E, Santisteban-Ponce J, Chea-Wood E and Guterriez M. N Engl J Med 2000;343:463-467 CONCLUSION The results of this study provide evidence that racecadotril, as an adjunct to oral rehydration solution, is effective and well tolerated in reducing the duration and severity of acute watery diarrhea in hospitalized infants and children. The antidiarrheal effect is obtained more rapidly than with oral rehydration alone, particularly in infants with rotavirus infection. RACECADOTRIL IN THE TREATMENT OF ACUTE WATERY DIARRHEA IN CHILDREN (Salazar-Lindo et al.) INFANTS AND CHILDREN
    • 53. Jean Pierre Cézard et al. Gastroenterology 2001; 120:799-805 EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN INFANTS AND CHILDREN
    • 54. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
      • STUDY DESIGN
        • – Randomized, double-blind, placebo-controlled, multicenter study
      • INCLUSION CRITERIA
        • – Severe acute diarrhea
        • – Aged 3 months to 4 years
        • – 3 or more watery stools per day
        • – Onset of diarrhea - less than 3 days
      • POPULATION
        • – Racecadotril + ORS: 84 patients
        • – Placebo + ORS: 82 patients
      Cézard JP et al. Gastroenterology 2001;120:799-805.
    • 55.
      • EVALUATION CRITERIA
        • – Stool output during the first 48 hrs (primary end point)
        • – Stool output during the first 24 hrs
        • – Dehydration status at 24 hrs (Urine Na + / K + ratio)
        • – Duration of diarrhea
        • – Number and characteristics of stools
      • TREATMENT
        • – Oral rehydration + racecadotril 1.5 mg/kg t.i.d.
        • – Oral rehydration + placebo t.i.d.
      Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    • 56.
      • Characteristics of population at inclusion
      CHARACTERISTIC Racecadotril + ORS Placebo + ORS [n = 84] [n = 82] Age [months] 12.0 ± 0.9 13.6 ± 1.0 Sex: [M / F] 51 / 38 50 / 33 Height [m] 0.73 ± 0.01 0.75 ± 0.01 Weight [kg] 8.54 ± 0.25 9.27 ± 0.25 Stool number [n] 6.0 ± 0.3 6.5 ± 0.4 Duration of diarrhea [days] 2.0 ± 0.2 1.9 ± 0.1 Patients with Rotavirus [n] 32 35 Patients with Adenovirus [n] 3 4 Mean + SEM Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    • 57.
      • Stool weight (g/hour) up to 48 hours
      Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    • 58.
      • Time to recovery in rotavirus-positive patients
      Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN Duration of diarrhea [median, hours] Racecadotril [n = 32] Placebo [n = 35] P 6.9 36 0.02
    • 59.
      • TOLERABILITY
      Number of Adverse Events (AE) Racecadotril + ORS 10 Placebo + ORS 11 The incidence of adverse events was similar in both groups of patients. Most common AE: Vomiting Cézard JP et al. Gastroenterology 2001;120:799-805. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    • 60. Cézard JP et al. Gastroenterology 2001;120:799-805. CONCLUSION This study demonstrates the efficacy (up to 50% reduction in stool output) and tolerability of racecadotril as an adjunct therapy to oral rehydration solution in the treatment of severe diarrhea in infants and children. EFFICACY AND TOLERABILITY OF RACECADOTRIL IN ACUTE DIARRHEA IN CHILDREN ( Cézard et al.) INFANTS AND CHILDREN
    • 61. ADULTS A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS David Prado for the Global Adult Racecadotril Study Group Scandinavian Journal of Gastroenterology 2002
    • 62. A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
      • STUDY DESIGN
        • – Multicenter (21 centers in 14 countries)
        • – Parallel groups
        • – Ambulatory patients
      Prado D. Scand J Gastroenterol 2002;37:656-61
      • INCLUSION CRITERIA
        • – 3 or more watery stools, with no visible blood, in the last 24 hours
        • – onset of diarrhea of presumed infectious origin, of at least 24 hours and less than 5 days
      ADULTS
    • 63.
      • TREATMENT
        • – Racecadotril: 100 mg, 3 times daily / Loperamide: 2 mg, 3 times daily
      ADULTS
      • ANALYZED POPULATION
        • – Racecadotril: 461 patients / Loperamide: 454 patients
      Prado D. Scand J Gastroenterol 2002;37:656-61 A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    • 64. ADULTS
      • EVALUATION CRITERIA
        • Main criterion :
        • – Duration of diarrhea until resolution, i.e 12 hours with no stools or 2 consecutive normal stools
        • Secondary criteria :
        • – Duration of abdominal distension and abdominal pain
        • – Associated symptoms
        • – Overall clinical response (success or failure)
      Prado D. Scand J Gastroenterol 2002;37:656-61 A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    • 65.
      • Characteristics of the patients at admission
      Included (n) 472 473 Excluded / lost from view (n) 16 / 10 17 / 10 Analyzed (n) 446 445 Age (years) * 36.4 ± 13.5 35.9 ± 12.1 Weight (kg) * 61.8 ± 12.5 62.8 ± 12.3 Male / Female 238 / 234 269 / 204 Duration of diarrhea prior to inclusion (hours) * 2.1 ± 1.1 2.1 ± 1.1 Number of watery stools in the preceding 24 hrs * 6.5 ± 4.3 6.4 ± 3.8 * means ± SEM. There was no significant difference between treatment groups PATIENTS Loperamide Racecadotril ADULTS Prado D. Scand J Gastroenterol 2002;37:656-61 A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    • 66. Duration of Diarrhea ADULTS A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.) Prado D. Scand J Gastroenterol 2002;37:656-61
    • 67. ADULTS Prado D. Scand J Gastroenterol 2002;37:656-61 Adverse events (%) Abdominal distension (duration in hrs) A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    • 68. Treatment-related adverse events with an incidence of more than 1% Prado D. Scand J Gastroenterol 2002;37:656-61 ADULTS A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    • 69. ADULTS CONCLUSION Racecadotril resolved the symptoms of acute diarrhea rapidly and effectively, and produced more rapid resolution of abdominal symptoms and less constipation than loperamide. Prado D. Scand J Gastroenterol 2002;37:656-61 A MULTINATIONAL COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN THE TREATMENT OF ACUTE DIARRHEA IN ADULTS (Prado D.)
    • 70. RACECADOTRIL’S SAFETY AND TOLERABILITY PROFILE
    • 71. COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN CHILDREN WITH ACUTE DIARRHEA (D. Turck et al.) D. Turck et al. Aliment Pharmacol Ther 1999; 13 (Suppl. 6), 27-32. Percentage of patients with constipation SAFETY AND TOLERABILITY
    • 72. Number of patients requiring concomitant medication during the study D. Turck et al. Aliment Pharmacol Ther 1999; 13 (Suppl. 6), 27-32. COMPARISON OF RACECADOTRIL AND LOPERAMIDE IN CHILDREN WITH ACUTE DIARRHEA (D. Turck et al.) SAFETY AND TOLERABILITY
    • 73. PHARMACOVIGILANCE 13 th Periodic Safety Update Report for Active Substance: Racecadotril. May 2007 Laboratoires Bioprojet Pharma. Adults Infants & Children TOTAL Period covered # of reported adverse events Prevalence March 1993 to March 2007 November 2000 to March 2007 75 30 105 0.00047 % 0.00032 % 0.00042 % Prevalence of adverse events associated with Racecadotril (France) Most common AE for adults and children: “Cutaneous disorders and miscellaneous allergic reactions” SAFETY AND TOLERABILITY
    • 74. E. Coli content of the proximal jejunum (gnotobiotic piglets) Duval-Iflah Y. Et al., Alimentary Pharmacology , 1999; (suppl. 6); 9-14 EFFECTS OF RACECADOTRIL AND LOPERAMIDE ON BACTERIAL PROLIFERATION ( Duval-Iflah Y. et al.) SAFETY AND TOLERABILITY
    • 75. 1. Lecomte JM, Int.J. Of Antimicrobial Agents , 2000; 14:81-87 2. Scwartz J-C, Int.J. Of Antimicrobial Agents , 2000; 14:75-79 3. Duval-Iflah Y. Et al., Alimentary Pharmacology , 1999; (suppl. 6): 9-14 4. Bergmann JF et al, Alimentary Pharmacology and Therapeutics , 1992; 6:305-313 5. Knisely JS, Drug and Alcohol Dependence ,1989;23:143-151 Blood-Brain Barrier Astrocyte processes Lipid soluble transport Carrier-mediated transport Does not induce CNS Toxicity 1,2,3 Racecadotril RACECADOTRIL DOES NOT CROSS THE BLOOD-BRAIN BARRIER Does not impair mental performance 4 Has no potential for abuse or physical dependence 5 SAFETY AND TOLERABILITY
    • 76. Therapeutic Index = LD 50 ED 50 Lecomte JM, Int.J. Of Antimicrobial Agents , 2000; 14:81-87 100 mg TID (adults) 20 times this dose was given to healthy adults with no ill effects Therapeutic dose Relevance of high therapeutic index The higher the Therapeutic Index, the lower the risk of overdose. RACECADOTRIL HAS A HIGH THERAPEUTIC INDEX (median lethal dose) (median effective dose) SAFETY AND TOLERABILITY
    • 77. SUMMARY AND CONCLUSIONS
    • 78. Prevention of Dehydration and Control of Diarrhea Normalization Diarrhea OVERALL CONCLUSIONS RACECADOTRIL IN THE TREATMENT OF ACUTE DIARRHEA Diarrhea Fluid replacement Racecadotril Fluid replacement
    • 79. Normalization Diarrhea Diarrhea Racecadotril Prevention of Dehydration and Control of Diarrhea OVERALL CONCLUSIONS RACECADOTRIL IN THE TREATMENT OF ACUTE DIARRHEA Fluid replacement Fluid replacement
    • 80. Loperamide Racecadotril Efficacy variable Motility 1 Secretion 2 Bacterial overgrowth 1 CNS effects 1 Constipation 2 - +++ - - - +++ + + + ++ RACECADOTRIL VERSUS LOPERAMIDE 1. Duval-Iflah Y. Et al., Alimentary Pharmacology , 1999; (suppl. 6); 9-14 2. D. Turck et al. Aliment Pharmacol Ther 1999; 13 (Suppl. 6), 27-32.   OVERALL CONCLUSIONS
    • 81. Active metabolite - Thiorphan Indication - treatment of acute diarrhea Recommended dose - 100 mg capsule every 8 hours Total daily dose: - should not exceed 300 mg Duration of treatment: - should not exceed 7 days Certificate of Product Registration of Racecadotril, Bureau of Food and Drugs, Department of Health. 2005 Racecadotril summary of product characteristics RACECADOTRIL OVERALL CONCLUSIONS
    • 82. Absorption - Rapid Maximum concentration - Maintained for at least four hours Concentration in plasma - Maintained for at least eight hours after administration RACECADOTRIL OVERALL CONCLUSIONS Racecadotril summary of product characteristics
    • 83. Efficacy - together with ORS, significantly reduces stool output and duration of diarrhea in children and adults Safety and tolerability - similar to placebo - fewer adverse events compared with loperamide - does not induce CNS toxicity - high therapeutic index RACECADOTRIL OVERALL CONCLUSIONS
    • 84. Racecadotril: A Novel Approach in the Treatment of Acute Diarrhea

    ×